Molecular and cellular pathogenesis of X-linked lymphoproliferative disease

Immunological Reviews

Volumn 203, Issue , 2005, Pages 180-199

  Nichols, Kim E ^a   Ma, Cindy S ^b   Cannons, Jennifer L ^c   Schwartzberg, Pamela L ^c   Tangye, Stuart G ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b CENTENARY INSTITUTE   (Australia)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; CD229 ANTIGEN; CD244 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD84 ANTIGEN; CELL SURFACE RECEPTOR; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE; RNA BINDING PROTEIN EWS; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; CHROMOSOME 1Q; CHROMOSOME XQ; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; DYSGAMMAGLOBULINEMIA; EAT 2 GENE; GENE; GENETIC LINKAGE; HUMAN; HYPOGAMMAGLOBULINEMIA; INFECTIOUS MONONUCLEOSIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOUSE; MULTIGENE FAMILY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SH2D1A GENE; T LYMPHOCYTE; VIRUS INFECTION; X CHROMOSOME LINKED DISORDER;

ANIMALS; ANTIGENS, CD; DYSGAMMAGLOBULINEMIA; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULINS; INFECTIOUS MONONUCLEOSIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOPROLIFERATIVE DISORDERS; MICE; MUTATION; RECEPTORS, CELL SURFACE;

EID: 13144302865     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00230.x     Document Type: Review

References (169)

1. Nichols KE, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998;95:13765-13770.
2. Coffey AJ, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998;20:129-135.
3. Sayos J, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998;395: 462-469.
4. Purtilo DT, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975;1:935-941.
5. Skare JC, Sullivan JL, Milunsky A. Mapping the mutation causing the X-linked lymphoproliferative syndrome in relation to restriction fragment length polymorphisms on Xq. Hum Genet 1989;82:349-353.
6. Skare JC, et al. Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37. Hum Genet 1989;82:354-358.
7. Purtilo DT, Grierson HL. Methods of detection of new families with X-linked lymphoproliferative disease. Cancer Genet Cytogenet 1991;51:143-153.
8. Sumegi J, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000;96:3118-3125.
9. Seemayer TA, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 1995;38:471-478.
10. Dutz JP, et al. Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood 2001;97:95-100.
11. Seemayer TA, Greiner TG, Gross TG, Davis JR, Lanyi A, Sumegi J. X-linked lymphoproliferative disease. In: Goedert JJ, ed. Infectious Causes of Cancer, Targets for Intervention. Totowa, N.J.: Humana Press, 2000: 51-61.
12. Schuster V, Kreth HW. X-linked lymphoproliferative disease. In: Ochs HD, Smith CIE, Puck J, eds. Primary Immunodeficiency Diseases, a Molecular and Genetic Approach. Oxford: Oxford University Press, 1999: 222-232.
13. Harrington DS, Weisenburger DD, Purtilo DT. Epstein-Barr virus-associated lymphoproliferative lesions. Clin Lab Med 1988;8:97-118.
14. Mroczek EC, Weisenburger DD, Grierson HL, Markin R, Purtilo DT. Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med 1987;111:530-535.
15. Okano M, Gross TG. Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis. Am J Hematol 1996;53:111-115.
16. Sumegi J, Gross TG, Seemayer TA. The molecular genetics of X-linked lymphoproliferative (Duncan's) disease. Cancer J Sci Am 1999;5:57-62.
17. Purtilo DT, et al. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry. Am J Med 1982;73:49-56.
18. Grierson HL, Skare J, Hawk J, Pauza M, Purtilo DT. Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease. Am J Med Genet 1991;40:294-297.
19. Grierson H, Purtilo DT. Epstein-Barr virus infections in males with X-linked lymphoproliferative syndrome. Ann Int Med 1987;106:538-545.
20. Harrington DS, Weisenburger DD, Purtilo DT. Malignant lymphoma in the X-linked lymphoproliferative syndrome. Cancer 1987;59:1419-1429.
21. Egeler RM, de Kraker J, Slater R, Purtilo DT. Documentation of Burkitt lymphoma with t(8;14)(q24:q32) in X-linked lymphoproliferative disease. Cancer 1992;70:683-687.
22. Brandau O, et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 1999;8:2407-2413.
23. Wu C, Sayos J, Wang N, Howie D, Coyle A, Terhorst C. Genomic organization and characterization of mouse SAP, the gene that is altered in X-linked lymphoproliferative disease. Immunogenetics 2000;51: 805-815.
24. Okamoto S, et al. Expression of the SH2D1A gene is regulated by a combination of transcriptional and post-transcriptional mechanisms. Eur J Immunol 2004;34:3176-3186.
25. Sayos J, et al. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol 2000;12: 1749-1757.
26. Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J Immunol 2000;165:2932-2936.
27. Shinozaki K, et al. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol 2002;14: 1215-1223.
28. Nagy N, Mattsson K, Maeda A, Liu A, Szekely L, Klein E. The X-linked lymphoproliferative disease gene product SAP is expressed in activated T and NK cells. Immunol Lett 2002;82:141-147.
29. Kis LL, Nagy N, Klein G, Klein E. Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines. Int J Cancer 2003;104:658-661.
30. Nagy N, et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer 2000;88: 439-447.
31. Nagy N, et al. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation. Int J Cancer 2002;100:433-440.
32. Shlapatska LM, et al. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol 2001;166:5480-5487.
33. Feldhahn N, et al. Silencing of B cell receptor signals in human naive B cells. J Exp Med 2002;196:1291-1305.
34. Williams H, et al. Analysis of immune activation and clinical events in acute infectious mononucleosis. J Infect Dis 2004;190:63-71.
35. Poy F, et al. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell 1999;4:555-561.
36. Hwang PM, et al. A 'diree-pronged' binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome. EMBO J 2002;21:314-323.
37. Li SC, et al. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A. Curr Biol 1999;9:1355-1362.
38. Latour S, Veillette A. Molecular and immunological basis of X-linked lymphoproliferative disease. Immunol Rev 2003;192:212-224.
39. Morra M, et al. Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J 2001;20:5840-5852.
40. Thompson AD, et al. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene. Oncogene 1996;13:2649-2658.
41. Tangye SG, van de Weerdt BCM, Avery DT, Hodgkin PD. CD84 is upregulated on a major population of human memory B cells and recruits the SH2-domain containing proteins SAP and EAT-2. Eur J Immunol 2002;32:1640-1649.
42. Tangye SG, Nichols KE, Hare NJ, van de Weerdt BC. Functional requirements for interactions between CD84 and Src homology 2 domain-containing proteins and their contribution to human T cell activation. J Immunol 2003;171:2485-2495.
43. Wang N, et al. The cell surface receptor SLAM controls T cell and macrophage functions. J Exp Med 2004;199:1255-1264.
44. Halasa NB, et al. Fatal hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection in a patient with a novel mutation in the signaling lymphocytic activation molecule-associated protein. Clin Infect Dis 2003;37:e136-141.
45. Eastwood D, et al. Prevalence of SAP gene defects in male patients diagnosed with common variable immunodeficiency. Clin Exp Immunol 2004;137:584-588.
46. Arico M, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 2001;97:1131-1133.
47. Morra M, et al. Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 2001;98:1321-1325.
48. Sumazaki R, et al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. Blood 2001;98:1268-1270.
49. Yin L, et al. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Genet 1999;105:501-505.
50. Parolini O, et al. Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's lymphoma. Ann Hematol 2002;81:441-447.
51. Ferrand V, Li C, Romeo G, Yin L. Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients. J Med Virol 2003;70:131-136.
52. Morra M, et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem 2001;276:36809-36816.
53. Li C, Iosef C, Jia CY, Gkourasas T, Han VK, Shun-Cheng Li S. Disease-causing SAP mutants are defective in ligand binding and protein folding. Biochemistry 2003;42:14885-14892.
54. Lewis J, et al. Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. Clin Immunol 2001;100:15-23.
55. Cocks BG, Chang CC, Carballido JM, Yssel H, de Vries JE, Aversa G. A novel receptor involved in T-cell activation. Nature 1995;376:260-263.
56. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 2001;167:5517-5521.
57. de la Fuente MA, Pizcueta P, Nadal M, Bosch J, Engel P. CD84 leukocyte antigen is a new member of the Ig superfamily. Blood 1997;90:2398-2405.
58. de la Fuente MA, et al. Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. Blood 2001;97:3513-3520.
59. Bottino C, et al. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med 2001;194:235-246.
60. Mathew PA, et al. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. J Immunol 1993;151:5328-5337.
61. Tangye SG, Phillips JH, Lanier LL. The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells. Semin Immunol 2000;12:149-157.
62. Punnonen J, et al. Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes. J Exp Med 1997;185:993-1004.
63. Schatzle JD, Sheu S, Stepp SE, Mathew PA, Bennett M, Kumar V. Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc Natl Acad Sci USA 1999;96:3870-3875.
64. Tovar V, et al. Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors. Immunogenetics 2002;54:394-402.
65. Lee JK, Boles KS, Mathew PA. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol 2004;34:2791.
66. Palou E, et al. Genomic characterization of CD84 reveals the existence of five isoforms differing in their cytoplasmic domains. Tissue Antigens 2000;55:118-127.
67. Sidorenko SP, Clark EA. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human T and B lymphocytes. J Immunol 1993;151:4614-4624.
68. Romero X, Benitez D, March S, Vilella R, Miralpeix M, Engel P. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens 2004;64:132-144.
69. + dendritic cells and is up-regulated by IL-1 beta. J Immunol 2001;167:1989-1995.
70. Hamalainen H, Meissner S, Lahesmaa R. Signaling lymphocytic activation molecule (SLAM) is differentially expressed in human Th1 and Th2 cells. J Immunol Methods 2000;242:9-19.
71. Howie D, et al. The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon gamma production. Blood 2002;100:2899-2907.
72. Aversa G, et al. SLAM and its role in T cell activation and Th cell responses. Immunol Cell Biol 1997;75:202-205.
73. Aversa G, Chang CJ, Carballido JM, Cocks B, de Vries JE. Engagement of the Signaling lymphocyte activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporine A-sensitive T cell proliferation and IFN-γ production. J Immunol 1997;158:4036-4044.
74. Henning G, et al. Signaling lymphocytic activation molecule (SLAM) regulates T cellular cytotoxicity. Eur J Immunol 2001;31:2741-2750.
75. Mavaddat N, et al. Signaling lymphocytic activation molecule (CDw150) is homophilic but self-associates with very low affinity. J Biol Chem 2000;275: 28100-28109.
76. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000;406:893-897.
77. Hahm B, Arbour N, Oldstone MB. Measles virus interacts with human SLAM receptor on dendritic cells to cause immunosuppression. Virology 2004;323:292-302.
78. Czar MJ, et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci USA 2001;98:7449-7454.
79. Wu C, et al. SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol 2001;2:410-414.
80. Latour S, Gish G, Helgason CD, Humphries RK, Pawson T, Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2001;2:681-690.
81. Latour S, et al. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat Cell Biol 2003;5:149-154.
82. Chan B, et al. SAP couples Fyn to SLAM immune receptors. Nat Cell Biol 2003;5:155-160.
83. Simarro M, et al. SAP increases FynT kinase activity and is required for phosphorylation of SLAM and Ly9. Int Immunol 2004;16:727-736.
84. Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol 1999;162:6981-6985.
85. Garni-Wagner BA, Purohit A, Mathew PA, Bennett M, Kumar V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Immunol 1993;151:60-70.
86. Nakajima H, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol 2000;30:3309-3318.
87. Kubota K, Katoh H, Muguruma K, Koyama K. Characterization of a surface membrane molecule expressed by natural killer cells in most inbred mouse strains: monoclonal antibody C9.1 identifies an allelic form of the 2B4 antigen. Immunology 1999;96:491-497.
88. Boles KS, et al. Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4. Tissue Antigens 1999;54:27-34.
89. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M. Activating interactions in human NK cell recognition, the role of 2B4-CD48. Eur J Immunol 1999;29:1676-1683.
90. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 1993;178:13970-1406.
91. Tangye SG, Cherwinski H, Lanier LL, Phillips JH. 2B4-mediated activation of human natural killer cells. Mol Immunol 2000;37:493-501.
92. Kambayashi T, Assarsson E, Chambers BJ, Ljunggren HG. Cutting edge: regulation of CD8(+) T cell proliferation by 2B4/CD48 interactions. J Immunol 2001;167: 6706-6710.
93. Lee KM, et al. Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells. J Immunol 2003;170:4881-4885.
94. Assarsson E, et al. NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J Immunol 2004;173:174-180.
95. Lee KM, et al. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med 2004;199:1245-1254.
96. Mooney JM, et al. The murine NK receptor 2B4 (CD244) exhibits inhibitory function independent of signaling lymphocytic activation molecule-associated protein expression. J Immunol 2004;173: 3953-3961.
97. Stepp SE, Schatzle JD, Bennett M, Kumar V, Mathew PA. Gene structure of the murine NK cell receptor 2B4: presence of two alternatively spliced isoforms with distinct cytoplasmic domains. Eur J Immunol 1999;29:2392-2399.
98. Parolini S, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000;192: 337-346.
99. Chen R, et al. Molecular dissection of 2B4 signaling: implications for signal transduction by SLAM-related receptors. Mol Cell Biol 2004;24:5144-5156.
100. Roda-Navarro P, et al. Dynamic redistribution of the activating 2B4/SAP complex at the cytotoxic NK cell immune synapse. J Immunol 2004;173:3640-3646.
101. Bottino C, et al. Analysis of the molecular mechanism involved in 2B4-mediated NK cell activation: evidence that human 2B4 is physically and functionally associated with the linker for activation of T cells. Eur J Immunol 2000;30:3718-3722.
102. Watzl C, Stebbins CC, Long EO. NK cell inhibitory receptors prevent tyrosine phosphorylation of the activation receptor 2B4 (CD244). J Immunol 2000;165: 3545-3548.
103. Klem J, Verrett PC, Kumar V, Schatzle JD. 2B4 is constitutively associated with linker for the activation of T cells in glycolipid-enriched microdomains: properties required for 2B4 lytic function. J Immunol 2002;169:55-62.
104. Valdez PA, et al. NTB-A, a new activating receptor in T cells that regulates autoimmune disease. J Biol Chem 2004;279:18662-18669.
105. Fraser CC, et al. Identification and characterization of SF2000 and SF2001, two new members of the immune receptor SLAM/CD2 family. Immunogenetics 2002;53:843-850.
106. Peck SR, Ruley HE. Ly108: a new member of the mouse CD2 family of cell surface proteins. Immunogenetics 2000;52:63-72.
107. Flaig RM, Stark S, Watzl C. Cutting edge: NTB-A activates NK cells via homophilic interaction. J Immunol 2004;172:6524-6527.
108. Falco M, et al. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells. Eur J Immunol 2004;34:1663-1672.
109. Zaiss M, et al. CD84 expression on human hematopoietic progenitor cells. Exp Hematol 2003;31:798-805.
110. de la Fuente MA, Tovar V, Pizcueta P, Nadal M, Bosch J, Engel P. Molecular cloning, characterization, and chromosomal localization of the mouse homologue of CD84, a member of the CD2 family of cell surface molecules. Immunogenetics 1999;49:249-255.
111. Martin M, et al. CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1. J Immunol 2001;167:3668-3676.
112. Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 2002;39:1-8.
113. Boles KS, Stepp SE, Bennett M, Kumar V, Mathew PA. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev 2001;181: 234-249.
114. Del Valle JM, Engel P, Martin M. The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). J Biol Chem 2003;278: 17430-17437.
115. Sayos J, et al. Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. Blood 2001;97:3867-3874.
116. Benoit L, Wang X, Pabst HF, Dutz J, Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol 2000;165:3549-3553.
117. Thorley-Lawson DA, Schooley RT, Bhan AK, Nadler LM. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell 1982;30:415-425.
118. Henniker AJ, Bradstock KF, Grimsley P, Atkinson MK. A novel non-lineage antigen on human leucocytes: characterization with two CD-48 monoclonal antibodies. Dis Markers 1990;8:179-190.
119. Sun H, Norris BJ, Atkinson K, Biggs JC, Smith GM. Preclinical antitumor activity of an antibody against the leukocyte antigen CD48. Clin Cancer Res 1998;4:895-900.
120. McHeyzer-Williams MG. B cells as effectors. Curr Opin Immunol 2003;15:354-361.
121. Liu YJ, Banchereau J. The paths and molecular controls of peripheral B-cell development. Immunologist 1996;4:55-66.
122. Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R. SAP is required for generating long-term humoral immunity. Nature 2003;421:282-287.
123. Yin L, et al. Mice deficient in the X-linked lymphoproliferative disease gene sap exhibit increased susceptibility to murine gammaherpesvirus-68 and hypogammaglobulinemia. J Med Virol 2003;71:446-455.
124. Hron JD, Caplan L, Gerth AJ, Schwartzberg PL, Peng SL. SH2D1A regulates T-dependent humoral autoimmunity. J Exp Med 2004;200:261-266.
125. Lindsten T, et al. Immune deficiency in the X-linked lymphoproliferative syndrome. II. Immunoregulatory T cell defects. J Immunol 1982;129:2536-2540.
126. Ochs HD, Sullivan JL, Wedgwood RJ, Seeley JK, Sakamoto K, Purtilo DT. X-linked lymphoproliferative syndrome: abnormal antibody responses to bacteriophage 0X174. In: WR J, RF S eds. Primary Immunodeficiency Diseases. New York: Alan R. Liss 1983: 205.
127. Purtilo DT, Grierson HL, Ochs H, Skare J. Detection of X-linked lymphoproliferative disease using molecular and immunovirologic markers. Am J Med 1989;87:421-424.
128. Cannons JL, et al. SAP regulates TH2 differentiation and PKC-theta-mediated activation of NF-kB1. Immunity 2004;21:693-706.
129. Howie D, Simarro M, Sayos J, Guirado M, Sancho J, Terhorst C. Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation. Blood 2002;99:957-965.
130. Sun Z, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000;404:402-407.
131. Ron D, et al. Direct interaction in T-cells between thetaPKC and the tyrosine kinase p59fyn. J Biol Chem 1999;274: 19003-19010.
132. Marsland BJ, Soos TJ, Spath G, Littman DR, Kopf M. Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J Exp Med 2004;200:181-189.
133. Artis D, et al. Differential requirement for NF-kappa B family members in control of helminth infection and intestinal inflammation. J Immunol 2002;169: 4481-4487.
134. Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001;2:45-50.
135. Leung TH, Hoffmann A, Baltimore D. One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers. Cell 2004;118:453-464.
136. Rousset F, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-1893.
137. +) B cells to secrete IgG1 and IgG3. J Exp Med 1994;179:757-762.
138. + T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection. Blood 2004;103:1625-1631.
139. Go NF, et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990;172:1625-1631.
140. Grimbacher B, Warnatz K, Peter HH. The immunological synapse for B-cell memory: the role of ICOS and its ligand for the longevity of humoral immunity. Curr Opin Allergy Clin Immunol 2003;3:409-419.
141. Hutloff A, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397: 263-266.
142. Beier KC, et al. Induction, binding specificity and function of human ICOS. Eur J Immunol 2000;30:3707-3717.
143. + effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 2003;197:181-193.
144. Yoshinaga SK, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999;402:827-832.
145. Wong SC, Oh E, Ng CH, Lam KP. Impaired germinal center formation and recall T-cell-dependent immune responses in mice lacking the costimulatory ligand B7-H2. Blood 2003;102:1381-1388.
146. Dong C, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001;409:97-101.
147. Dong C, Temann UA, Flavell RA. Cutting edge: critical role of inducible costimulator in germinal center reactions. J Immunol 2001;166:3659-3662.
148. McAdam AJ, et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001;409:102-105.
149. Tafuri A, et al. ICOS is essential for effective T-helper-cell responses. Nature 2001;409:105-109.
150. Smith KM, Brewer JM, Webb P, Coyle AJ, Gutierrez-Ramos C, Garside P. Inducible costimulatory molecule-B7-related protein 1 interactions are important for the clonal expansion and B cell helper functions of naive, Th1, and Th2 T cells. J Immunol 2003;170:2310-2315.
151. Liang L, Porter EM, Sha WC. Constitutive expression of the B7h ligand for inducible costimulator on naive B cells is extinguished after activation by distinct B cell receptor and interleukin 4 receptor-mediated pathways and can be rescued by CD40 signaling. J Exp Med 2002;196:97-108.
152. Grimbacher B, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003;4:261-268.
153. Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 1998;188:1691-1703.
154. Sharifi R, et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 2004;103:3821-3827.
155. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-562.
156. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-568.
157. Carnaud C, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163:4647-4650.
158. Smyth MJ, et al. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002;99: 1259-1266.
159. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
160. Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999;190:1189-1196.
161. Bendelac A, Hunziker RD, Lantz O. Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells. J Exp Med 1996;184:1285-1293.
162. Stanic AK, Bezbradica JS, Park JJ, Van Kaer L, Boothby MR, Joyce S. Cutting edge: the ontogeny and function of Va14Ja18 natural T lymphocytes require signal processing by protein kinase C theta and NF-kappa B. J Immunol 2004;172:4667-4671.
163. Stanic AK, et al. NF-kappa B controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J Immunol 2004;172: 2265-2273.
164. Sivakumar V, Hammond KJ, Howells N, Pfeffer K, Weih F. Differential requirement for Rel/nuclear factor kappa B family members in natural killer T cell development. J Exp Med 2003;197: 1613-1621.
165. Elewaut D, et al. NIK-dependent RelB activation defines a unique signaling pathway for the development of V alpha 14i NKT cells. J Exp Med 2003;197:1623-1633.
166. Roberts TJ, Lin Y, Spence PM, Van Kaer L, Brutkiewicz RR. CD1d1-dependent control of the magnitude of an acute antiviral immune response. J Immunol 2004;172:3454-3461.
167. Pasquinelli V, et al. Expression of signaling lymphocytic activation molecule-associated protein interrupts IFN-gamma production in human tuberculosis. J Immunol 2004;172:1177-1185.
168. Ramhorst RE, Garcia VE, Corigliano A, Etchepareborda JJ, Irigoyen M, Fainboim L. Expression of SLAM as a functional and phenotypic marker in women with recurrent miscarriage. J Reprod Immunol 2004;62:139-149.
169. Garcia VE, et al. Signaling lymphocycic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J Immunol 2001;167:5719-5724.